Filing summary
Important identity discrepancy: The supplied filing is Frequency Therapeutics, Inc.’s Form 10-Q, not a filing for Korro Bio, Inc. It covers the quarter ended September 30, 2019 and was signed November 18, 2019.
Business context and reporting period
Frequency Therapeutics was a clinical-stage biotechnology company developing small-molecule therapies using its progenitor cell activation (PCA) platform. Its lead candidate, FX-322, targets sensorineural hearing loss (SNHL); it was also researching a potential multiple sclerosis (MS) candidate. The financial statements are unaudited. The company had no product-sale revenue.
Financial metrics
| Metric | Three months ended September 30, 2019 | Nine months ended September 30, 2019 |
|---|---|---|
| Revenue | $24.238 million | $24.238 million |
| Research and development expense | $5.221 million | $12.588 million |
| General and administrative expense | $4.269 million | $9.837 million |
| Royalty expense | $16.000 million | $16.000 million |
| Operating loss | $1.252 million | $14.187 million |
| Net loss | $0.575 million | $13.253 million |
| Net loss attributable to common stockholders | $1.589 million | $14.267 million |
| Loss per common share, basic and diluted | $0.73 | $7.17 |
The $80 million Astellas upfront payment was recognized over the service and study period, rather than all at receipt. Third-quarter revenue included $16.0 million associated with the MIT royalty and $8.2 million recognized under the company’s progress-based method. The remaining upfront consideration was deferred. No gross margin is presented; the filing reports operating expenses rather than a product-sales cost structure.
| Balance-sheet and cash-flow item | Amount / period |
|---|---|
| Cash and cash equivalents, September 30 | $142.274 million |
| Short-term marketable securities, September 30 | $23.047 million |
| Total cash, cash equivalents and short-term investments | $165.3 million |
| Total current assets / current liabilities, September 30 | $166.721 million / $72.204 million |
| Total liabilities, September 30 | $78.826 million |
| Debt outstanding, September 30 | None |
| Operating cash flow, nine months | +$63.958 million |
| Investing cash flow, nine months | −$23.690 million |
| Financing cash flow, nine months | +$59.817 million |
| Cash increase, nine months | +$100.085 million |
Operating cash flow was substantially affected by the $55.762 million increase in deferred revenue and $16.0 million in royalty payable; it should not be read as recurring cash generation. Cash and securities included $23.047 million of U.S. Treasury securities. The company reported an accumulated deficit of $63.355 million.
Material changes versus the prior comparable period
- Revenue rose from zero in the 2018 comparative periods, primarily because of the Astellas collaboration and its $80 million upfront payment.
- Third-quarter 2019 net loss improved to $0.575 million from $5.136 million, while nine-month net loss improved to $13.253 million from $13.721 million. The quarter’s result reflects collaboration revenue and investment income, alongside the $16 million MIT royalty charge.
- Nine-month R&D expense increased $3.629 million year over year, to $12.588 million; G&A increased $5.177 million, to $9.837 million. Management cited FX-322 development, higher employee costs and stock compensation, and public-company and professional-service costs.
- Cash and cash equivalents increased from $42.189 million at December 31, 2018 to $142.274 million at September 30, 2019. The company also held $23.047 million of short-term securities at quarter-end.
Outlook, commentary, risks and unusual items
- Financing and runway: In October 2019, after quarter-end, the company completed an IPO of 6.325 million shares at $14 per share and received approximately $79.2 million net. Management said existing resources, including IPO proceeds, were expected to fund planned operations into 2022; its earlier liquidity disclosure said resources would cover at least 12 months from the financial statements’ issuance. These are estimates dependent on assumptions and spending.
- Astellas collaboration: Astellas received an exclusive license to specified products, including FX-322, outside the United States. The agreement provides up to $230 million in development milestones, up to $315 million in commercial milestones, and tiered royalties. The company retains U.S. commercialization rights and shares certain development costs. Astellas may terminate at will on 60 days’ notice.
- Clinical outlook: The company reported a statistically significant word-recognition improvement and tolerability in a 23-patient Phase 1/2 FX-322 trial. It began a Phase 2a SNHL trial in October 2019 and expected top-line results in the second half of 2020. It planned to submit an IND for its MS candidate in the second half of 2021. FX-322 received FDA Fast Track designation in October 2019.
- Risks: The company expected continued losses and rising R&D and public-company costs. Clinical, regulatory, financing, intellectual-property and commercialization outcomes were uncertain. It relied on third-party manufacturers, including a single manufacturer for clinical-trial product supply, and had no approved products or product-sale revenue.
- Other items: The $16 million MIT royalty on the Astellas upfront payment was expensed and remained payable at September 30. In November 2019, the company amended its Woburn lease, adding 7,550 square feet and extending the term to February 2025; stated annual rent was approximately $545,000 with 3% annual increases. Management reported effective disclosure controls, no material change in internal control over financial reporting, and no material legal proceedings.
Important facts for investors to verify
- Confirm the issuer: this source is Frequency Therapeutics, Inc. (Nasdaq: FREQ), not Korro Bio, Inc.
- Review the Astellas agreement’s revenue-recognition schedule, remaining deferred revenue, milestone conditions, cost-sharing provisions and termination rights.
- Assess the quality and sustainability of reported operating cash flow, given its dependence on deferred revenue and unpaid royalty accruals.
- Track Phase 2a FX-322 results, subsequent clinical plans, and the timing and regulatory progress of the MS program.
- Evaluate post-IPO cash use, the stated runway assumptions, manufacturing concentration, and the effects of preferred-stock conversion and IPO dilution.